Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
This article was originally published in Pharmaceutical Approvals Monthly
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without
You may also be interested in...
Among halted development programs is Phase III antidepressant saredutant; decision on Plavix follow-on idrabiotaparinux awaits FDA safety determination.
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has
Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength